04.24.26 -- Biosimilars And Complex Medicines For All With Sarfaraz Niazi

Join Life Science Leader Chief Editor Ben Comer on April 30th at 11am eastern for the Return of Radiopharmaceuticals: Overcoming Operational Challenges And New Opportunities virtual event. Panelists will discuss emerging technologies and radioisotopes, what new market opportunities exist, and what manufacturing and delivery challenges remain for radiopharmaceutical developers. Registration is free.

Amid the mRNA and oligonucleotide therapeutic boom, sponsors and manufacturers are exploring how to make critical raw materials—capping agents, lipid nanoparticles, and RNA polymerase—more effective.

North Carolina reinforced its life sciences leadership with nearly $3.8B in investments, expanded manufacturing, and major workforce initiatives.

As U.S. biotech investment continues to rise, cross-border collaboration and trial design innovations are expected to further solidify Australia’s role in the early-stage biotech development pipeline.

Explore a strategic approach to accelerating biologics formulation by gaining early insight into molecular properties and optimizing high-concentration conditions with minimal protein input.

See how the EU HTA Regulation reshapes market access through PICO consolidation, with strategies for evidence generation, comparator selection, and real‑world data integration.

Advances in synthetic biology and enabling technologies are expanding fermentation’s role, reshaping modern practices and unlocking new applications across industries.